RT Journal Article T1 Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. A1 Judd, A A1 Lodwick, R A1 Noguera-Julian, A A1 Gibb, D M A1 Butler, K A1 Costagliola, D A1 Sabin, C A1 van Sighem, A A1 Ledergerber, B A1 Torti, C A1 Mocroft, A A1 Podzamczer, D A1 Dorrucci, M A1 De Wit, S A1 Obel, N A1 Dabis, F A1 Cozzi-Lepri, A A1 García, F A1 Brockmeyer, N H A1 Warszawski, J A1 Gonzalez-Tome, M I A1 Mussini, C A1 Touloumi, G A1 Zangerle, R A1 Ghosn, J A1 Castagna, A A1 Fätkenheuer, G A1 Stephan, C A1 Meyer, L A1 Campbell, M A A1 Chene, G A1 Phillips, A K1 Europe K1 Perinatal HIV infection K1 Virological failure K1 Young people K1 Adolescente K1 Adulto K1 Fármacos anti-VIH K1 Niño K1 Enfermedades transmisibles K1 Intervalos de confianza K1 Europa K1 Infecciones por VIH K1 VIH-1 K1 Recién nacido K1 Heterosexualidad K1 Inhibidores de proteasas K1 ADN polimerasa dirigida por ADN K1 Inhibidores de la transcriptasa inversa K1 Factores de riesgo K1 Carga viral AB OBJECTIVES:The aim of the study was to determine the time to, and risk factors for, triple-class virological failure (TCVF) across age groups for children and adolescents with perinatally acquired HIV infection and older adolescents and adults with heterosexually acquired HIV infection.METHODS:We analysed individual patient data from cohorts in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). A total of 5972 participants starting antiretroviral therapy (ART) from 1998, aged < 20 years at the start of ART for those with perinatal infection and 15-29 years for those with heterosexual infection, with ART containing at least two nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (bPI), were followed from ART initiation until the most recent viral load (VL) measurement. Virological failure of a drug was defined as VL > 500 HIV-1 RNA copies/mL despite ≥ 4 months of use. TCVF was defined as cumulative failure of two NRTIs, an NNRTI and a bPI.RESULTS:The median number of weeks between diagnosis and the start of ART was higher in participants with perinatal HIV infection compared with participants with heterosexually acquired HIV infection overall [17 (interquartile range (IQR) 4-111) vs. 8 (IQR 2-38) weeks, respectively], and highest in perinatally infected participants aged 10-14 years [49 (IQR 9-267) weeks]. The cumulative proportion with TCVF 5 years after starting ART was 9.6% [95% confidence interval (CI) 7.0-12.3%] in participants with perinatally acquired infection and 4.7% (95% CI 3.9-5.5%) in participants with heterosexually acquired infection, and highest in perinatally infected participants aged 10-14 years when starting ART (27.7%; 95% CI 13.2-42.1%). Across all participants, significant predictors of TCVF were those with perinatal HIV aged 10-14 years, African origin, pre-ART AIDS, NNRTI-based initial regimens, higher pre-ART viral load and lower pre-ART CD4.CONCLUSIONS:The results suggest a beneficial effect of starting ART before adolescence, and starting young people on boosted PIs, to maximize treatment response during this transitional stage of development. PB Wiley SN 1464-2662 YR 2017 FD 2017-03-14 LK http://hdl.handle.net/10668/2688 UL http://hdl.handle.net/10668/2688 LA en NO Judd A, Lodwick R, Noguera-Julian A, Gibb DM, Butler K, Costagliola D et al. Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. HIV Med. 2017;18(3):171-180 DS RISalud RD Jul 6, 2025